Pozelimab

Pozelimab es un fármaco en desarrollo de Regeneron Pharmaceuticals. Tiene 14 ensayos clínicos registrados, 5 en marcha; lo más avanzado, fase 4.

REGN Regeneron Pharmaceuticals

Sus ensayos

Para qué	Fase	Estado
VIENNA NCT07230834	Fase 1	Reclutando pacientes
SIENNA NCT06541704	Fase 3	Reclutando pacientes
Hemoglobinuria paroxística nocturna NCT05744921	Fase 3	Reclutando pacientes
Hemoglobinuria paroxística nocturna NCT07154745	Fase 3	Reclutando pacientes
A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease NCT07142343	Fase 4	Reclutando pacientes
Hemoglobinuria paroxística nocturna NCT04811716	Fase 2	Completado
A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers NCT04940364	Fase 1	Completado
Hemoglobinuria paroxística nocturna NCT04888507	Fase 2	Completado
Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease) NCT04209634	Fase 2/3	Completado
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers NCT04601844	Fase 1	Completado
Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants NCT04491838	Fase 1	Completado
Hemoglobinuria paroxística nocturna NCT06028594	no aplica	Ya no disponible
CHAPLE Disease NCT06003881	no aplica	Aprobado para comercializar
Compassionate Use of Pozelimab NCT05232110	no aplica	Aprobado para comercializar

¿Cuándo se esperan resultados? Está en el calendario, para quien tiene cuenta. Crear una cuenta.

Ensayos del registro público de ClinicalTrials.gov; noticias, de los documentos que la empresa presenta ante la SEC. No son recomendaciones de inversión.